Why ALEC rose 38.7% on Oct 5 2026: genentech licensing deal
ALEC+38.7%on Mon Oct 5 2026
Alector, Inc. Common Stock was up 38.7% on the day at $2.51, ranked #1 on 1413× its usual five-minute volume, when TapeRank recorded this spike at 07:06 ET during the pre-market session. TapeRank recorded 2 events for ALEC that day, between 07:01 and 07:06 ET, and each is in the timeline below.
THE DAY ON THE LIST · 2 EVENTS
- 07:01 ETUNEXPLAINED MOVE · PRE-MARKET
$2.27 · ▲ 25.7% ON THE DAY · 266× 5M RVOL · RANK #2
UNEXPLAINEDNO FILINGS · RULEALEC is up 25.7% on the day on 274x its normal volume for this time of day. No filings or headlines were found in SEC EDGAR filings and Benzinga wire headlines in the last 24 hours, so this is order flow rather than a disclosed catalyst.
WHYNo filings or headlines within 24 hours of the move.ANALYZED 07:01 ET · <1 MIN AGO · RULE, NO MODELTHE ROW AND SESSION LEVELS AT 07:01 ET
LAST2.27DAY▲ 25.7%5 MIN▲ 22.31%5M RVOL266×5M $VOL$233KFLOAT*111.7MRANK#2SESSIONPRE-MARKETVWAP2.32HOD2.88LOD1.86OR HIGH—OR LOW—PREV CLOSE1.81PM HIGH2.88PM LOW1.86GAP▲ 25.69% (indicated)* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO
- 07:06 ETMOVER · PRE-MARKET
$2.51 · ▲ 38.7% ON THE DAY · 1413× 5M RVOL · RANK #1
STRETCHEDCONFIDENCE5/5ALEC is up 38.7% with a further 16.18% surge in five minutes after announcing an exclusive global license for its AL050 Parkinson’s program to Genentech. The deal has a credible strategic partner but provides no disclosed financial terms, milestone value, or clinical validation in the supplied report, making the move substantially larger than the quantified news supports.
WHYUp 38.7% and accelerating on a licensing announcement with no disclosed economics or clinical results is a much larger move than the measurable substance of the news.ANALYZED 07:06 ET · <1 MIN AGO · OPENAI/GPT-5.6-LUNATHE ROW AND SESSION LEVELS AT 07:06 ET
LAST2.51DAY▲ 38.7%5 MIN▲ 16.18%5M RVOL1413×5M $VOL$2.8MFLOAT*111.7MRANK#1SESSIONPRE-MARKETVWAP2.32HOD2.88LOD1.86OR HIGH—OR LOW—PREV CLOSE1.81PM HIGH2.88PM LOW1.86GAP▲ 38.12% (indicated)* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO
THE SESSION
- 09:30 ETOpened at $2.73, +50.5% on the previous close of $1.81
- 09:30 ETRegular-session high, $2.73
- 15:53 ETRegular-session low, $1.96
- 15:59 ETLast trade of the regular session, $1.98, +9.4% on the previous close of $1.81
- Volume: 39.9M shares in regular hours, 48.5M before the open
ALEC opened at $2.73, already 50.5% above the previous close, after rising to $2.51 by 07:06 ET when TapeRank ranked it first and recorded a 38.7% move. TapeRank tied the early surge to Alector’s announcement of an exclusive global license for its AL050 Parkinson’s program to Genentech, while noting that no financial terms, milestone value or clinical validation were disclosed; it also had no filing or headline within 24 hours at the earlier recording. With no halts, the stock declined through the session to a $1.96 low at 15:53 ET and finished at $1.98, still 9.4% above the previous close.
WRITTEN THU OCT 15 2026 18:01 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE
FILINGS AND NEWS · 24H BEFORE THE MOVE
No SEC filings or wire news in the 24 hours before this was recorded. A move on news that never reached the wire shows nothing here, which is what UNEXPLAINED means.
On the tape right now
WHERE THE LIST STOODWED NOV 4 2026 · 13:49 ETRECORDED LIVE · 742 QUALIFY
Open the full list